Apices Soluciones
Apices Soluciones is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Sponsor Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
- Start (EU)
- Latest update
- Estimated end
An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible for cisplatin-based chemotherapy.
Sponsor Fundacion Para El Progreso De La Oncologia En Cantabria
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2)
Sponsor Queen Mary University Of London
- Start (EU)
- Latest update
- Estimated end
A Phase IIIB study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Newly Diagnosed pMMR Advanced or Recurrent Endometrial Cancer in Spain. DUoENDE Study
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase IIIb study of durvalumab as consolidation treatment for patients diagnosed with limited stage small cell lung cancer who have not progressed following definitive concurrent or sequential platinum-based chemoradiation therapy in Spain (ALBORAN).
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase IIIB study to evaluate the use of capivasertib in combination with fulvestrant in patients with HR+ / HER2- advanced breast cancer who have relapsed/progressed on ET and CDK4/6 inhibitor reflecting Real World Clinical Practice in Spain: CAPItana Study.
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
The SOUND-MCL study: A single-arm, open-label, multicenter, phase II study of acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation
Sponsor Grupo Espanol De Investigacion En Cancer De Ovario
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies
Sponsor Transgene
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Phase II Trial assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer
Sponsor Fundacion Cris De Investigacion Para Vencer El Cancer
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Apices Soluciones?
The 2026-10-09 snapshot links Apices Soluciones to 10 distinct CTIS trials. Recorded services include Clinical monitoring, Safety reporting & pharmacovigilance, Data management, Medical writing, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Apices Soluciones?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Apices Soluciones conducted?
The linked trials record locations in 5 countries, including Spain, France, Germany, Italy, Portugal. These are trial locations, not confirmed office locations or countries where Apices Soluciones delivered services.
What can this page tell me about Apices Soluciones's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Apices Soluciones. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Apices Soluciones S.L.